Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports
Portfolio Pulse from
Pfizer has announced it will cease global development of its gene therapy for bleeding disorders, Beqvez, as reported by Nikkei.
February 20, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer is discontinuing the global development of its gene therapy Beqvez, which was aimed at treating bleeding disorders. This decision may impact investor sentiment regarding Pfizer's pipeline and future growth in gene therapy.
The discontinuation of Beqvez suggests potential setbacks in Pfizer's gene therapy pipeline, which could negatively affect investor confidence in the company's future growth prospects in this area. This decision may lead to a short-term negative impact on Pfizer's stock price.
CONFIDENCE 95
IMPORTANCE 70
RELEVANCE 90